ERBB2 and breast carcinoma: Recently, FDA approved pertuzumab in combination with trastuzumab, for patients with ERBB2-positive breast cancer with high-risk recurrence, and pertuzumab treatment alone showed significant improvement of invasive disease-free survival in breast cancer patients [143].